The emerging role of mammalian target of rapamycin inhibitors in the treatment of sarcomas

Targeted Oncology

Volumn 6, Issue 1, 2011, Pages 29-39

  Vemulapalli, Sushma ^a   Mita, Alain ^a   Alvarado, Yesid ^a   Sankhala, Kamalesh ^a   Mita, Monica ^a  

^a CTRC Institute for Drug Development   (United States)

Author keywords

mTOR inhibitors; Ridaforolimus; Sarcomas; Temsirolimus

Indexed keywords

ALPHA INTERFERON; BKM 120; CAMPTOTHECIN; CISPLATIN; CIXUTUMUMAB; DOXORUBICIN; EVEROLIMUS; FLUOROURACIL; IMATINIB; INITIATION FACTOR 4E BINDING PROTEIN 1; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PLACEBO; PROTEIN BAD; PROTEIN KINASE B; RAPAMYCIN; RAPAMYCIN DERIVATIVE; RIDAFOROLIMUS; SORAFENIB; SUNITINIB; TEMSIROLIMUS; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR; XL 147; XL 765;

ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW SUPPRESSION; BREAST CARCINOMA; CANCER INHIBITION; CANCER RESISTANCE; CARCINOGENESIS; COLON CARCINOMA; DIARRHEA; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG CYTOTOXICITY; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG POTENTIATION; DRUG SAFETY; DRUG SELECTIVITY; DRUG SENSITIVITY; DRUG TARGETING; DRUG TOLERABILITY; DYSPNEA; EWING SARCOMA; FATIGUE; GASTROINTESTINAL STROMAL TUMOR; GLIOBLASTOMA; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; KAPOSI SARCOMA; KIDNEY CARCINOMA; LEIOMYOSARCOMA; LIPOSARCOMA; LOW DRUG DOSE; LUNG INFILTRATE; MALIGNANT TRANSFORMATION; MANTLE CELL LYMPHOMA; MIXED MULLERIAN TUMOR; MOUTH PAIN; MUCOSA INFLAMMATION; NAUSEA; NONHUMAN; OSTEOSARCOMA; OVARY CANCER; PANCREAS CARCINOMA; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROTEIN EXPRESSION; RECOMMENDED DRUG DOSE; RHABDOMYOSARCOMA; SARCOMA; SIGNAL TRANSDUCTION; SOFT TISSUE SARCOMA; SOLID TUMOR; STOMATITIS; SYNOVIAL SARCOMA; THROMBOCYTOPENIA; UNSPECIFIED SIDE EFFECT;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; HUMANS; MOLECULAR TARGETED THERAPY; SARCOMA; SIGNAL TRANSDUCTION; SIROLIMUS; TOR SERINE-THREONINE KINASES;

EID: 79957509564     PISSN: 17762596     EISSN: 1776260X     Source Type: Journal    
DOI: 10.1007/s11523-011-0179-4     Document Type: Article

References (100)

1. JA D (2009) Different view of Sarcoma statistics. http://sarcomahelp.org/ sarcoma-statistics.html January 2010
2. National Cancer Institute (2009) SEER Cancer statistics. http://seer.cancer.gov/statistics/
3. A Jemal R Siegel E Ward Y Hao J Xu T Murray MJ Thun 2008 Cancer statistics, 2008 CA Cancer J Clin 58 2 71 96 18287387 10.3322/CA.2007.0010 (Pubitemid 351521864)
4. JC Yang AE Chang AR Baker WF Sindelar DN Danforth SL Topalian T DeLaney E Glatstein SM Steinberg MJ Merino SA Rosenberg 1998 Randomized prospective study of the benefit of adjuvant radiation therapy in the treatment of soft tissue sarcomas of the extremity J Clin Oncol 16 1 197 203 9440743 1:CAS:528: DyaK1cXmsVeqtg%3D%3D (Pubitemid 28041599)
5. Brennan MF AK, Maki RG, O Sullivan B (2008) Soft tissue sarcoma. 8 th edition edn. Devita VT Jr.,Lawrence TS, Rosenburg SA, eds. Cancer. Principles and practice of Oncology, Philadelphia, PA
6. ML Hensley R Maki E Venkatraman G Geller M Lovegren C Aghajanian P Sabbatini W Tong R Barakat DR Spriggs 2002 Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial J Clin Oncol 20 12 2824 2831 12065559 10.1200/JCO.2002.11.050 1:CAS:528:DC%2BD38Xlt1KitLg%3D (Pubitemid 34651511)
7. ML Hensley JA Blessing K Degeest O Abulafia PG Rose HD Homesley 2008 Fixed-dose rate gemcitabine plus docetaxel as second-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study Gynecol Oncol 109 3 323 328 18394689 10.1016/j.ygyno.2008.02.024 1:CAS:528: DC%2BD1cXmvVKrsL8%3D
8. ML Hensley JA Blessing R Mannel PG Rose 2008 Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II trial Gynecol Oncol 109 3 329 334 18534250 10.1016/j.ygyno.2008.03.010 1:CAS:528:DC%2BD1cXmvVKrsLw%3D (Pubitemid 351754961)
9. DCRC Fingar AR Tee L Cheatham C Tsou J Blenis 2004 mTOR controls cell cycle progression through its cell growth effectors S6K1 and 4E-BPI/eukaryotic translation initiation factor 4E Mol Cell Biol 24 1 200 216 14673156 10.1128/MCB.24.1.200-216.2004 1:CAS:528:DC%2BD2cXhtVWnuw%3D%3D (Pubitemid 38010048)
10. THM Schmelzle 2000 TOR, a central controller of cell growth Cell 13 103 253 262 10.1016/S0092-8674(00)00117-3
11. GJSC Wiederrecht GJ Brunn 1995 Mechanism of action of rapamycin: new insights into the regulation of G1-phase progression in eukaryotic cells Prog Cell Cycle Res 1 53 71 9552353 1:CAS:528:DyaK28Xkt1Kgu70%3D
12. BTSD Hennessy PT Ram Y Lu GB Mills 2005 Exploting the the PI3K/AKT pathway for cancer drug discovery Nat RevDrug Discov 4 12 988 1004 10.1038/nrd1902 1:CAS:528:DC%2BD2MXht1yktbjI
13. M Scaltriti J Baselga 2006 The epidermal growth factor receptor pathway: a model for targeted therapy Clin Cancer Res 12 18 5268 5272 17000658 10.1158/1078-0432.CCR-05-1554 1:CAS:528:DC%2BD28XpvFShs74%3D (Pubitemid 44497237)
14. H Yu T Rohan 2000 Role of the insulin-like growth factor family in cancer development and progression J Natl Cancer Inst 92 18 1472 1489 10995803 10.1093/jnci/92.18.1472 1:CAS:528:DC%2BD3cXntFKqsrw%3D
15. HBFS Jefferies PB Dennis, et al. 1997 Rapamycin suppresses 5′TOP mRNA translation through inhibition of p70s6k EMBO J 16 12 3693 3704 9218810 10.1093/emboj/16.12.3693 1:CAS:528:DyaK2sXktlCnsLw%3D (Pubitemid 27250062)
16. ACRB Gingras N Sonenberg 1999 effectors of mRNA recruitment to ribosomes and regulation of translation Annu Rev Biochem 68 913 963 10872469 10.1146/annurev.biochem.68.1.913 1:CAS:528:DyaK1MXlvFajtL4%3D (Pubitemid 29449212)
17. D Sabatini 2006 mTOR and Cancer: insights into a complex relationship Nat Rev Cancer 6 729 734 16915295 10.1038/nrc1974 1:CAS:528:DC%2BD28XosVOmsb8%3D (Pubitemid 44286004)
18. R Loewith E Jacinto S Wullschleger A Lorberg JL Crespo D Bonenfant W Oppliger P Jenoe MN Hall 2002 Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control Mol Cell 10 3 457 468 12408816 10.1016/S1097-2765(02)00636-6 1:CAS:528:DC%2BD38XnvFSlt74%3D (Pubitemid 35284167)
19. Z Zeng D dos Sarbassov IJ Samudio KW Yee MF Munsell C Ellen Jackson FJ Giles DM Sabatini M Andreeff M Konopleva 2007 Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML Blood 109 8 3509 3512 17179228 10.1182/blood-2006-06-030833 1:CAS:528:DC%2BD2sXksFWhs78%3D (Pubitemid 46572543)
20. DHSD Kim SM Ali JE King RR Latek H Erdjument-Bromage P Tempst DM Sabatini 2002 mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery Cell 110 2 163 175 12150925 10.1016/S0092-8674(02)00808-5 1:CAS:528:DC%2BD38XlvV2htr4%3D (Pubitemid 34876545)
21. DHSD Kim SM Ali RR Latek KV Guntur H Erdjument-Bromage P Tempst DM Sabatini 2003 GbetaL, a positive regulator of the rapamycin-sensitive pathway required for the nutrientsensitive nteraction between raptor and mTOR Mol Cell 11 4 895 904 12718876 10.1016/S1097-2765(03)00114-X 1:CAS:528: DC%2BD3sXjslGhsLY%3D (Pubitemid 36566312)
22. TRLM Peterson CC Thoreen Y Sancak SA Kang WM Kuehl NS Gray DM Sabatini 2009 DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival Cell 137 873 886 19446321 10.1016/j.cell.2009.03.046 1:CAS:528:DC%2BD1MXosVCltb0%3D
23. YTC Sancak TR Peterson RA Lindquist SA Kang E Spooner SA Carr DM Sabatini 2007 PRAS40 is an insulinregulated inhibitor of the mTORC1 protein kinase Mol Cell 25 903 915 17386266 10.1016/j.molcel.2007.03.003 1:CAS:528: DC%2BD2sXktFCgsbc%3D (Pubitemid 46436534)
24. ELS Vander Haar S Bandhakavi TJ Griffin DH Kim 2007 Insulin signalling to mTOR mediated by the Akt/PKB substrate PRAS40 Nat Cell Biol 9 316 323 17277771 10.1038/ncb1547 1:CAS:528:DC%2BD2sXit12rsr0%3D (Pubitemid 46344611)
25. MATC Frias JD Jaffe W Schroder T Sculley SA Carr DM Sabatini 2006 mSin1 is necessary for Akt/PKB phosphorylation, and its isoforms define three distinct mTORC2s Curr Biol 16 958 970 10.1016/j.cub.2006.08.001 (Pubitemid 44354144)
26. E Jacinto R Loewith A Schmidt S Lin MA Ruegg A Hall MN Hall 2004 Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive Nat Cell Biol 6 11 1122 1128 15467718 10.1038/ncb1183 1:CAS:528:DC%2BD2cXptFentL8%3D (Pubitemid 39468014)
27. DDAS Sarbassov DH Kim DA Guertin RR Latek H Erdjument-Bromage P Tempst DM Sabatini 2004 Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptorindependent pathway that regulates the cytoskeleton Curr Biol 14 1296 1302 15268862 10.1016/j.cub.2004.06.054 1:CAS:528:DC%2BD2cXmtVamsLs%3D (Pubitemid 38991819)
28. Q Yang K Inoki T Ikenoue KL Guan 2006 Identification of Sin1 as an essential TORC2 component required for complex formation and kinase activity Genes Dev 20 20 2820 2832 17043309 10.1101/gad.1461206 1:CAS:528: DC%2BD28XhtFWqsbbL (Pubitemid 44771744)
29. CB Kozlowski J Avruch 1998 Regulation of protein metabolism in muscle JBiol Chem 273 14484 14494
30. MP Byfield JT Murray JM Backer 2005 hVps34 is a nutrient-regulated lipid kinase required for activation of p70 S6 kinase J Biol Chem 280 38 33076 33082 16049009 10.1074/jbc.M507201200 1:CAS:528:DC%2BD2MXhtVWiurvL (Pubitemid 41368357)
31. T Nobukuni M Joaquin M Roccio SG Dann SY Kim P Gulati MP Byfield JM Backer F Natt JL Bos FJ Zwartkruis G Thomas 2005 Amino acids mediate mTOR/raptor signaling through activation of class 3 phosphatidylinositol 3OH-kinase Proc Natl Acad Sci USA 102 40 14238 14243 16176982 10.1073/pnas.0506925102 1:CAS:528:DC%2BD2MXhtFChu7fM (Pubitemid 41429682)
32. P Gulati LD Gaspers SG Dann M Joaquin T Nobukuni F Natt SC Kozma AP Thomas G Thomas 2008 Amino acids activate mTOR complex 1 via Ca2+/CaM signaling to hVps34 Cell Metab 7 5 456 465 18460336 10.1016/j.cmet.2008.03.002 1:CAS:528:DC%2BD1cXmtFeiurg%3D (Pubitemid 351598024)
33. GM Findlay L Yan J Procter V Mieulet RF Lamb 2007 A MAP4 kinase related to Ste20 is a nutrient-sensitive regulator of mTOR signalling Biochem J 403 1 13 20 17253963 10.1042/BJ20061881 1:CAS:528:DC%2BD2sXksFOks7g%3D (Pubitemid 46569862)
34. K Baird S Davis CR Antonescu UL Harper RL Walker Y Chen AA Glatfelter PH Duray PS Meltzer 2005 Gene expression profiling of human sarcomas: insights into sarcoma biology Cancer Res 65 20 9226 9235 16230383 10.1158/0008-5472.CAN-05- 1699 1:CAS:528:DC%2BD2MXhtFWmu7%2FO (Pubitemid 41507988)
35. R Ricci N Maggiano F Castri A Rinelli M Murazio F Pacelli AE Potenza FM Vecchio LM Larocca 2004 Role of PTEN in gastrointestinal stromal tumor progression Arch Pathol Lab Med 128 4 421 425 15043466 1:CAS:528: DC%2BD2cXjslSitbs%3D (Pubitemid 38451129)
36. T Saito Y Oda K Kawaguchi T Takahira H Yamamoto S Tamiya K Tanaka S Matsuda A Sakamoto Y Iwamoto M Tsuneyoshi 2003 PTEN/MMAC1 gene mutation is a rare event in soft tissue sarcomas without specific balanced translocations Int J Cancer 104 2 175 178 12569572 10.1002/ijc.10918 1:CAS:528:DC%2BD3sXhvFykt7w%3D (Pubitemid 36249792)
37. X Wan LJ Helman 2003 Levels of PTEN protein modulate Akt phosphorylation on serine 473, but not on threonine 308, in IGF-II-overexpressing rhabdomyosarcomas cells Oncogene 22 50 8205 8211 14603261 10.1038/sj.onc.1206878 1:CAS:528:DC%2BD3sXoslSis7s%3D (Pubitemid 37487311)
38. S Okuno 2006 Mammalian traget of Rapamycin inhibitors in sarcomas Curr Op Oncol 18 4 360 362 10.1097/01.cco.0000228742.72165.cf 1:CAS:528: DC%2BD28XkvVWlur4%3D (Pubitemid 44297247)
39. K Scotlandi P Picci 2008 Targeting insulin-like growth factor 1 receptor in sarcomas Curr Opin Oncol 20 4 419 427 18525338 10.1097/CCO.0b013e328302edab 1:CAS:528:DC%2BD1cXms1yhuro%3D
40. Y Xie B Skytting G Nilsson B Brodin O Larsson 1999 Expression of insulin-like growth factor-1 receptor in synovial sarcoma: association with an aggressive phenotype Cancer Res 59 15 3588 3591 10446966 1:CAS:528: DyaK1MXltFCgurw%3D (Pubitemid 29381857)
41. S Fulda 2008 Targeting apoptosis resistance in rhabdomyosarcoma Curr Cancer Drug Targets 6 536 544 10.2174/156800908785699333
42. R Ganti SX Skapek J Zhang CE Fuller J Wu CA Billups PP Breitfeld JD Dalton WH Meyer JD Khoury 2006 Expression and genomic status of EGFR and ErbB-2 in alveolar and embryonal rhabdomyosarcoma Mod Pathol 19 9 1213 1220 16729016 10.1038/modpathol.3800636 1:CAS:528:DC%2BD28XotlCgurs%3D (Pubitemid 44268191)
43. S Montanner 2007 Akt/TSC/mTOR activation by the KSHV G protein -coupled receptor: emerging into the molecular oncogenesis and treatment of Kaposi's sarcoma Cell Cycle 6 4 438 443 10.4161/cc.6.4.3843
44. I Sansal WR Sellers 2004 The biology and clinical relevance of the PTEN tumor suppressor pathway J Clin Oncol 22 14 2954 2963 15254063 10.1200/JCO.2004.02.141 1:CAS:528:DC%2BD2cXpsVWktbk%3D (Pubitemid 41079915)
45. X Wan LJ Helman 2007 The biology behind mTOR inhibition in sarcoma Oncologist 12 8 1007 1018 17766661 10.1634/theoncologist.12-8-1007 (Pubitemid 47359144)
46. E Hernando E Charytonowicz ME Dudas S Menendez I Matushansky J Mills ND Socci N Behrendt L Ma RG Maki PP Pandolfi C Cordon-Cardo 2007 The AKT-mTOR pathway plays a critical role in the development of leiomyosarcomas Nat Med 13 6 748 753 17496901 10.1038/nm1560 1:CAS:528:DC%2BD2sXmtFeksrg%3D (Pubitemid 46889749)
47. L Girnita A Girnita M Wang JM Meis-Kindblom LG Kindblom O Larsson 2000 A link between basic fibroblast growth factor (bFGF) and EWS/FLI-1 in Ewing's sarcoma cells Oncogene 19 37 4298 4301 10980604 10.1038/sj.onc.1203755 1:CAS:528:DC%2BD3cXms1ygtrk%3D
48. DPTD Hughes TJ Giordano LH Baker KT McDonagh 2004 Cell surface expression of epidermal growth fatcor receptor and Her-2 with nuclear expression of Her-4 in primary osteosarcoma Cancer Res 64 6 2047 2053 15026342 10.1158/0008-5472. CAN-03-3096 1:CAS:528:DC%2BD2cXitFCgtbo%3D (Pubitemid 38339452)
49. S DuBois G Demetri 2007 Markers of angiogenesis and clinical features in patients with sarcoma Cancer 109 5 813 819 17265525 10.1002/cncr.22455 1:CAS:528:DC%2BD2sXjsVKns70%3D (Pubitemid 46333523)
50. A Potti AK Ganti K Tendulkar K Sholes S Chitajallu M Koch S Kargas 2004 Determination of vascular endothelial growth factor (VEGF) overexpression in soft tissue sarcomas and the role of overexpression in leiomyosarcoma J Cancer Res Clin Oncol 130 1 52 56 14600832 10.1007/s00432-003-0504-0 1:CAS:528:DC%2BD3sXps1yhtrc%3D (Pubitemid 38161248)
51. C Kuhnen M Lehnhardt E Tolnay T Muehlberger PM Vogt KM Muller 2000 Patterns of expression and secretion of vascular endothelial growth factor in malignant soft-tissue tumours J Cancer Res Clin Oncol 126 4 219 225 10782895 10.1007/s004320050036 1:CAS:528:DC%2BD3cXjtl2lurs%3D (Pubitemid 30183025)
52. A Iyoda K Hiroshima M Baba T Fujisawa T Yusa H Ohwada 2001 Expression of vascular endothelial growth factor in thoracic sarcomas Ann Thorac Surg 71 5 1635 1639 11383813 10.1016/S0003-4975(01)02533-4 1:STN:280: DC%2BD3MzhtVertQ%3D%3D (Pubitemid 32452556)
53. U Graeven N Andre E Achilles C Zornig W Schmiegel 1999 Serum levels of vascular endothelial growth factor and basic fibroblast growth factor in patients with soft-tissue sarcoma J Cancer Res Clin Oncol 125 10 577 581 10473871 10.1007/s004320050319 1:CAS:528:DyaK1MXmt1ersbk%3D (Pubitemid 29434883)
54. S Sleijfer W Van der Graaf J Blay 2008 Angiogenesis inhibition in non-GIST soft tissue sarcomas Oncologist 13 11 1193 1200 18987047 10.1634/theoncologist.2008-0188 1:CAS:528:DC%2BD1MXmtVGjug%3D%3D
55. J Pouyssegur F Dayan NM Mazure 2006 Hypoxia signalling in cancer and approaches to enforce tumour regression Nature 441 7092 437 443 16724055 10.1038/nature04871 1:CAS:528:DC%2BD28XkvVyrsr0%3D (Pubitemid 44050138)
56. Falcon BL, Barr S, Gokhale PC, Chou J, Fogarty J, Depeille P, Miglarese M, Epstein DM, McDonald DM Reduced VEGF production, angiogenesis, and vascular regrowth contribute to the antitumor properties of dual mTORC1/mTORC2 Inhibitors. Cancer Res 71 (5):1573-1583
57. J Heitman NR Movva MN Hall 1991 Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast Science 253 5022 905 909 1715094 10.1126/science.1715094 1:CAS:528:DyaK3MXlsl2hsr8%3D (Pubitemid 21917235)
58. EJ Brown MW Albers TB Shin K Ichikawa CT Keith WS Lane SL Schreiber 1994 A mammalian protein targeted by G1-arresting rapamycin-receptor complex Nature 369 6483 756 758 8008069 10.1038/369756a0 1:CAS:528:DyaK2cXlsFSiu74%3D (Pubitemid 24225367)
59. GSA Stallone B Infante, et al. 2005 Sirolimus for Kaposi's sarcoma in renal-transplant recipients N Engl J Med 352 1317 1323 15800227 10.1056/NEJMoa042831 1:CAS:528:DC%2BD2MXislCjsb4%3D (Pubitemid 40411498)
60. C Récher O Beyne-Rauzy C Demur, et al. 2005 Antileukemic activity of rapamycin in acute myeloid leukemia Blood 105 2527 2534 15550488 10.1182/blood-2004-06-2494 (Pubitemid 40387055)
61. NK Ratain MJ K Knightley-Moshier 2007 A phase 1b study of oral rapamycin (sirolimus) in patients with advanced malignancies J Clin Oncol ASCO Annual Meeting Proceedings Part I 25 18S 3510
62. M Mita QS Chu, et al. 2008 Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies J Clin Oncol 26 361 367 18202410 10.1200/JCO.2007.12.0345 1:CAS:528: DC%2BD1cXitVGntLk%3D (Pubitemid 351171685)
63. L Dudkin MB Dilling PJ Cheshire FC Harwood M Hollingshead SG Arbuck R Travis EA Sausville PJ Houghton 2001 Biochemical correlates of mTOR inhibition by the rapamycin ester CCI-779 and tumor growth inhibition Clin Cancer Res 7 6 1758 1764 11410517 1:CAS:528:DC%2BD3MXltV2hsL4%3D (Pubitemid 32708646)
64. JJ Gibbons C Discafini R Peterson R Hernandez J Skotnocki J Frost 1999 The effect of CCI-779, a novel macrolide antitumor agent on the growth human tumor cells in vitro and in nude mouse xenograft models in vitro Proc Am Ass Cancer Res 40 301 abstr. 2000
65. B Geoerger K Kerr CB Tang KM Fung B Powell LN Sutton PC Phillips AJ Janss 2001 Antitumor activity of the rapamycin analog CCI-779 in human primitive neuroectodermal tumor/medulloblastoma models as single agent and in combination chemotherapy Cancer Res 61 4 1527 1532 11245461 1:CAS:528:DC%2BD3MXhvVeltb8%3D (Pubitemid 34292583)
66. G Hudes M Carducci P Tomczak J Dutcher R Figlin A Kapoor E Staroslawska J Sosman D McDermott I Bodrogi Z Kovacevic V Lesovoy IG Schmidt-Wolf O Barbarash E Gokmen T O'Toole S Lustgarten L Moore RJ Motzer 2007 Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma N Engl J Med 356 22 2271 2281 17538086 10.1056/NEJMoa066838 1:CAS:528:DC%2BD2sXmtVKkurs%3D (Pubitemid 46849157)
67. B Escudier S Oudard 2008 Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial Lancet 372 449 456 18653228 10.1016/S0140-6736(08)61039-9
68. G Hess 2009 Temsirolimus for the treatment of mantle cell lymphoma Exp Rev Hem 2 631 640 10.1586/ehm.09.57 1:CAS:528:DC%2BD1MXhsVyqsLbO
69. Okuno SH (2006) A multicenter phase 2 consortium (P2C) study of the mTOR inhibitor CCI-779 in advanced soft tissue sarcomas. J Clin Oncol ASCO Annual Meeting Proceedings Part I. 24(18S) (June 20 Supplement): abstr. 9504
70. MVJ Van Glabbeke I Judson OS Nielsen 2002 Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas Eur J Cancer 38 543 549 11872347 10.1016/S0959-8049(01)00398-7 (Pubitemid 34185394)
71. TVJ O'Reilly M Muller, et al. 2002 In vivo activity of RAD001, an orally active rapamycin derivative, in experimental tumor models [abstract] Proc Am Assoc Cancer Res 43 71
72. HSC Lane A Theuer, et al. 2002 Antiangiogenic activity of RAD001, an orally active anticancer agent [abstract] Proc Am Assoc Cancer Res 43 184
73. A AvOe (2005) A phase I/II trial of the oral mTOR-inhibitor everolimus (E) and imatinib mesylate (IM) in patients (pts) with gastrointestinal stromal tumor (GIST) refractory to IM. Study update. J Clin Oncol ASCO Annual Meeting Proceedings. 23(16S) Part I of II (June 1 Supplement): abstr. 9033
74. H. Dumez e (2008) A phase I-II study of everolimus (RAD001) in combination with imatinib in patients (pts) with imatinib-resistant gastrointestinal stromal tumors (GIST) J Clin Oncol (Meeting Abstracts) 26 (15): abstr 10519
75. Clackson T MC, Rivera VM, et al (2003) Broad anti-tumor activity of AP2357, an mTOR inhibitor in clinical development[abstract]. J Clin Oncol Proceedings
76. Mita MM, Poplin E et al (2008) Deforolimus trial 106- A Phase I trial evaluating 7 regimens of oral Deforolimus (AP23573, MK-8669). J Clin Oncol (Meeting Abstracts) 26
77. CM Hartford AA Desai L Janisch T Karrison VM Rivera L Berk JW Loewy H Kindler WM Stadler HL Knowles C Bedrosian MJ Ratain 2009 A phase I trial to determine the safety, tolerability, and maximum tolerated dose of deforolimus in patients with advanced malignancies Clin Cancer Res 15 4 1428 1434 19228743 10.1158/1078-0432.CCR-08-2076 1:CAS:528:DC%2BD1MXitVOktL8%3D
78. Chawla SP TA, Staddon AP et al. (2007) Survival results with AP23573, a novel mTOR inhibitor, in patients (pts) with advanced soft tissue or bone sarcomas: update of phase II trial. J Clin Oncol (Meeting Abstracts) 25
79. Ridaforolimus in Treatment of Sarcoma-SUCCEED (Sarcoma Multi-Center Clinical Eval. of the Efficacy of Ridaforolimus)(8669-011). http:// clinicaltrials.gov/ct2/show/NCT00538239
80. A Pivotal Trial to Determine the Efficacy and Safety of AP23573 When Administered as Maintenance Therapy to Patients With Metastatic Soft-Tissue or Bone Sarcomas (2011) http://clinicaltrials.gov/ct2/show/NCT00538239.
81. Safety, Tolerability and Maximum Tolerated Dose of Oral AP23573 in Combination With Doxorubicin http://clinicaltrials.gov/ct2/show/NCT00288431
82. Perotti A, Sessa C, Colombo N, Del Conte G, Delmonte A et al (2010) Phase Ib study of RAD001 (R) with pegylated-liposomal doxorubicin (PLD) in patients with advanced solid tumors. J Clin Oncol 28(15): abstr 5050
83. D Yee RE Favoni GS Lebovic F Lombana DR Powell CP Reynolds N Rosen 1990 Insulin-like growth factor I expression by tumors of neuroectodermal origin with the t(11;22) chromosomal translocation. A potential autocrine growth factor J Clin Invest 86 6 1806 1814 2174908 10.1172/JCI114910 1:CAS:528: DyaK3MXktVajsA%3D%3D
84. G Hamilton R Mallinger S Hofbauer M Havel 1991 The monoclonal HBA-71 antibody modulates proliferation of thymocytes and Ewing's sarcoma cells by interfering with the action of insulin-like growth factor I Thymus 18 1 33 41 1656551 1:CAS:528:DyaK38XkvVKi
85. K Scotlandi D Remondini G Castellani MC Manara F Nardi L Cantiani M Francesconi M Mercuri AM Caccuri M Serra S Knuutila P Picci 2009 Overcoming resistance to conventional drugs in Ewing sarcoma and identification of molecular predictors of outcome J Clin Oncol 27 13 2209 2216 19307502 10.1200/JCO.2008.19.2542 1:CAS:528:DC%2BD1MXlvFOgs78%3D
86. K Scotlandi MC Manara G Nicoletti PL Lollini S Lukas S Benini S Croci S Perdichizzi D Zambelli M Serra C Garcia-Echeverria F Hofmann P Picci 2005 Antitumor activity of the insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 in musculoskeletal tumors Cancer Res 65 9 3868 3876 15867386 10.1158/0008-5472.CAN-04-3192 1:CAS:528:DC%2BD2MXjslGks7Y%3D (Pubitemid 40616368)
87. S Benini MC Manara N Baldini V Cerisano S Massimo M Mercuri PL Lollini P Nanni P Picci K Scotlandi 2001 Inhibition of insulin-like growth factor I receptor increases the antitumor activity of doxorubicin and vincristine against Ewing's sarcoma cells Clin Cancer Res 7 6 1790 1797 11410521 1:CAS:528:DC%2BD3MXltV2hsLo%3D (Pubitemid 32708650)
88. RT Kurmasheva L Dudkin C Billups LV Debelenko CL Morton PJ Houghton 2009 The insulin-like growth factor-1 receptor-targeting antibody, CP-751,871, suppresses tumor-derived VEGF and synergizes with rapamycin in models of childhood sarcoma Cancer Res 69 19 7662 7671 19789339 10.1158/0008-5472.CAN-09- 1693 1:CAS:528:DC%2BD1MXht1Skt7jM
89. Olmos D, Postel-Vinay S, Molife LR, Okuno SH, Schuetze SM, Paccagnella ML, Batzel GN, Yin D, Pritchard-Jones K, Judson I, Worden FP, Gualberto A, Scurr M, de Bono JS, Haluska P Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study. Lancet Oncol 11 (2):129-135
90. FE Bertrand LS Steelman WH Chappell SL Abrams JG Shelton ER White DL Ludwig JA McCubrey 2006 Synergy between an IGF-1R antibody and Raf/MEK/ERK and PI3K/Akt/mTOR pathway inhibitors in suppressing IGF-1R-mediated growth in hematopoietic cells Leukemia 20 7 1254 1260 16642049 10.1038/sj.leu.2404217 1:CAS:528:DC%2BD28XlvFGjtLg%3D (Pubitemid 43905829)
91. Naing P et al (2010) Dual inhibition of mTOR and IGFR pathways. J Clin Oncol 28:15s: abstr 3007
92. A phase II study of temsirolimus and IGF-1 Receptor antibody cixutumumab in patients with metastatic sarcomas. http://clinicaltrials.gov/ct2/show/ NCT01016015
93. DA Guertin DM Sabatini 2007 Defining the role of mTOR in cancer Cancer Cell 12 1 9 22 17613433 10.1016/j.ccr.2007.05.008 1:CAS:528:DC%2BD2sXotVyqsr0%3D (Pubitemid 47001784)
94. KE O'Reilly F Rojo QB She D Solit GB Mills D Smith H Lane F Hofmann DJ Hicklin DL Ludwig J Baselga N Rosen 2006 mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt Cancer Res 66 3 1500 1508 16452206 10.1158/0008-5472.CAN-05-2925 (Pubitemid 43259931)
95. S Ogita P LoRusso 2011 Targeting phosphatidylinositol 3 kinase (PI3K)-Akt beyond rapalogs Targ Oncol 10.1007/s11523-011-0176-7
96. Brana I LP, Baselga J, et al (2010) A phase I dose-escalation study of the safety, pharmacokinetics (PK), and pharmacodynamics of XL765 (SAR245409), a PI3K/TORC1/TORC2 inhibitor administered orally to patients (pts) with advanced malignancies. In: J Clin Oncol 28(15s): abstr 3030
97. Edelman G BC, Shapiro G, A (2010) phase I dose-escalation study of XL147 (SAR245408), a PI3K inhibitor administered orally to patients (pts) with advanced malignancies. J Clin Oncol 28(15s): abstr 3004
98. Burris H RJ, Sharma S, et al (2010) First-in-human phase I study of the oral PI3K inhibitor BEZ235 in patients (pts) with advanced solid tumors. J Clin Oncol 28(15s): abstr 3005
99. Baselga J DJM, Rodon J, (2010) A first-in-human phase I study of BKM120, an oral pan-class I PI3K inhibitor, in patients (pts) with advanced solid tumors. J Clin Oncol 28(15s): abstr 3003
100. Delbaldo C (2011) Predictive biomarkers for the activity of mammalian target of rapamycin (mTOR) inhibitors. Targ Oncol. doi: 10.1007/s11523-011-0177- 6